Evidence map›Paper›PMID 40764849›Full record

ReviewCancer metastasis reviews2025

Socioeconomic impact of artificial intelligence-driven point-of-care testing devices for liquid biopsy in the OncoCheck system.

Sima Singh, Ada Raucci, Alessandra Glovi, Gabriella Iula, Luciano Mutti, Michelino De Laurentiis, Antonio Giordano, Stefano Cinti

Abstract readReview
In one paragraph

Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sima SinghDepartment of Pharmacy, University of Naples 'Federico II', Via D. Montesano 49, 80131, Naples, Italy.
Ada RaucciDepartment of Pharmacy, University of Naples 'Federico II', Via D. Montesano 49, 80131, Naples, Italy.
Alessandra GloviDepartment of Pharmacy, University of Naples 'Federico II', Via D. Montesano 49, 80131, Naples, Italy.
Gabriella IulaDepartment of Pharmacy, University of Naples 'Federico II', Via D. Montesano 49, 80131, Naples, Italy.
Luciano MuttiCenter for Biotechnology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.
Michelino De LaurentiisDepartment of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
Antonio GiordanoCenter for Biotechnology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA. president@shro.org.
Stefano CintiDepartment of Pharmacy, University of Naples 'Federico II', Via D. Montesano 49, 80131, Naples, Italy. stefano.cinti@unina.it.

Funding

Fondazione AIRC per la ricerca sul cancro ETS ID. 27586HORIZON EUROPE Marie Sklodowska-Curie Actions No. 101110684
6 · The paper itself

Abstract

Cancer disparities in low- and middle-income countries (LMICs) persist because of socioeconomic inequalities and limited access to screening infrastructure, which requires equitable diagnostic solutions. As researchers, we need to develop interventions which mirror successful strategies from high-income countries (HICs) to address mortality inequalities. Routine cancer diagnosis functions as a fundamental element of effective management yet remains unavailable to numerous populations in LMICs. This review proposes the conceptual "OncoCheck" model, which combines the terms Oncology "Onco" and Screening "Check" as an integrated approach to early cancer detection. It provides a theoretically sound practical approach that combines liquid biopsy with point-of-care testing (POCT) and artificial intelligence (AI) to achieve high-sensitivity diagnostics in resource-limited settings without requiring advanced infrastructure. The review advocates OncoCheck as a promising and practical cancer screening solution which shows potential to increase accessibility and decrease costs while improving survival rates through early detection. Moving beyond technical specifications, the manuscript assesses its socioeconomic impact, showing reduced medical costs and improved treatment outcomes. The paper describes its implementation framework together with a validation strategy and performance benchmarks. The analysis further focuses on the implementation barriers like algorithmic bias mitigation, infrastructure limitations, and ethical AI deployment. The OncoCheck system delivers equitable cancer care by implementing a hospital-at-home model which functions with real-world health systems.

Indexed as

Artificial IntelligenceEarly Detection of CancerNeoplasmsPoint-of-Care TestingHumansLiquid BiopsySocioeconomic FactorsArtificial intelligence in cancerCancer inequitiesLiquid biopsyOncoCheckPoint-of-care testing

Identifiers

PMID40764849
PMCPMC12325499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.